Aquestive Therapeutics Inc (AQST) (Q3 2026) Earnings Call Highlights: Revenue Dip Masks

Aquestive Therapeutics (AQST) reported Q3 2026 revenue of $7.6M, down from $12.8M in Q3 2025, with a net loss of $16.5M. The company resubmitted its Anifilm NDA, with an FDA action date of March 16, 2027, and received a $10M upfront payment for out-licensing Libervant. AQST expects to end 2026 with over $70M in cash and is preparing for Anifilm's U.S. launch, hiring 75 sales reps. The FDA review timeline and pricing strategy remain uncertain.

Original reporting
Published Nov 6, 2026, 7:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 6, 2026, 7:29 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Aquestive Therapeutics Inc (AQST) (Q3 2026) Earnings Call Highlights: Revenue Dip Masks — source image
Decision brief

The 30-second read

$AQSTBearishMed
01

Why it matters

Earnings miss may trigger sell‑off, but cash position and licensing cash inflow provide a floor.

02

Market read

Primary micro‑cap earnings release with mixed news; downside bias but mitigated by cash and licensing cash.

03

What to watch

Potential earlier FDA decision on Anifilm could catalyze upside if approved ahead of schedule.

Relevance 6/10Novelty 7/10Timing: after-hours release

Background

Aquestive Therapeutics is a micro‑cap biotech focused on epinephrine auto‑injector Anifilm and related licensing deals.

Company-level read

Ticker impact

$AQSTBearishHigh confidence
Context

Q3 2026 earnings released with revenue down to $7.6M and net loss of $16.5M, plus updates on Anifilm NDA resubmission and licensing deal.

Expected impact

likely pressure as the market prices in the revenue decline and widened loss

Evidence & confidence

The earnings numbers are worse than prior year and the guidance is limited; however, the $10M upfront licensing payment and cash balance mitigate the downside.

Market effects

Biotech sector may see broader scrutiny on late-stage allergy drug pipelines.

Limited to US biotech investors.

Minimal global impact.

Counterpoint

The licensing deal and cash runway could support a short-term bounce despite earnings miss.

Key entities

  • Aquestive Therapeutics Inc

    Biotech firm reporting Q3 2026 results.

  • Eton Pharmaceuticals

    Licensee of Libervant receiving $10M upfront.

Related articles

$AQSTMed

Aquestive Therapeutics Eyes Needle-Free Allergy Treatment Launch Ahead of 2027 FDA Decision

Aquestive Therapeutics (AQST) presented data on Anaphylm, a needle-free allergy treatment, showing faster absorption and higher blood pressure changes than EpiPen. The company expects FDA decision by 2027 and projects a $2B U.S. market by 2029. AQST plans to launch in Canada, Europe, and the U.K. in 2024. The company also discussed its sales strategy and pipeline, including Libervant and AQST-108.

$AQSTMed

Aquestive Therapeutics, Inc. Q3 2026 Earnings Call Summary

Aquestive Therapeutics reported Q3 2026 earnings, highlighting milestones like the NDA resubmission for Annamil and out-licensing of Libervant. Revenue grew 14% year-to-date due to increased license and royalty income. The company plans a spring 2027 launch for Annamil, with $95M in contingent funding available. Management expects to end 2026 with over $70M in cash. The Libervant deal provided a $10M upfront payment, with potential for $47.5M in milestones.

$AQSTMed

Aquestive Therapeutics Reports Third Quarter 2026 Financial Results

Aquestive Therapeutics, Inc. (AQST) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Aquestive Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update • Anaphylm resubmission accepted with PDUFA goal date of March 16, 2027 • Anaphylm would be the first and only oral rescue medication for the treatment of severe allergic

$AQSTHigh

A dissolving film could become the first oral rescue medicine for severe allergies.

Aquestive Therapeutics (AQST) announced its Q3 2026 financial results and provided updates on its pipeline. The FDA accepted the resubmission of Anaphylm, an oral epinephrine product for severe allergies, with a PDUFA goal date of March 16, 2027. If approved, Anaphylm would be the first oral rescue medication for anaphylaxis. The company is also progressing with commercial preparations and international filings.

$AQSTMed

H.C. Wainwright reiterates Aquestive stock rating on FDA review

H.C. Wainwright reiterated a Buy rating and $10 price target for Aquestive Therapeutics (AQST) after the FDA accepted its drug candidate resubmission. AQST shares are down 15% this week but analysts see undervaluation. The company reported Q2 revenue of $13.82M, up 38% YoY, but a wider loss per share than expected. Cantor Fitzgerald also reiterated an Overweight rating with an $11 target.